Similar companies
| Company | Transaction Value | |
|---|---|---|
 |
OcugenOCGN |
-$5.5M |
 |
Gilead SciencesGILD |
-$4.04B |
 |
AmgenAMGN |
-$189M |
 |
Editas MedicineEDIT |
-$7M |
 |
Crispr TherapeuticsCRSP |
-$171M |
Are Calidi Biotherapeutics Insiders Buying or Selling?
Calidi Biotherapeutics (CLDI) has had no reported insider transactions in the past 90 days. The most recent was Allan Camaisa, who sold 850 shares at $1.46 on December 12, 2025.
Insider trading patterns can signal confidence or concern from the people who know the company best. AltIndex tracks insider transactions as one of 25+ alternative data signals in the CLDI AI Score. For government officials trading this stock, see CLDI congressional trading.
Who’s Trading Calidi Biotherapeutics Stock?
| Insider | Activity | Trades | Last Trade |
|---|---|---|---|
| Allan Camaisa | Sold $17,000 | 2 | Dec 12, 2025 |
| Andrew Jackson | Mixed $0 | 1 | Aug 21, 2025 |
| Eric Poma | Mixed $0 | 1 | Aug 21, 2025 |
| James Schoeneck | Mixed $0 | 1 | Aug 21, 2025 |
| Scott Leftwich | Mixed $0 | 1 | Aug 21, 2025 |
Recent Calidi Biotherapeutics Insider Transactions
| Insider | Transaction Date | Type | Shares | Price | Value |
|---|---|---|---|---|---|
| Allan Camaisa | Dec 12, 2025 | Sell | 850 | $1.46 | $1,200 |
| Scott Leftwich | Aug 21, 2025 | Buy | 125,000 | $0 | $0 |
| James Schoeneck | Aug 21, 2025 | Buy | 75,000 | $0 | $0 |
| Eric Poma | Aug 21, 2025 | Buy | 25,000 | $0 | $0 |
| Andrew Jackson | Aug 21, 2025 | Buy | 2,500 | $0 | $0 |
| Allan Camaisa | Dec 17, 2024 | Sell | 10,000 | $1.62 | $16,000 |
Frequently Asked Questions: Calidi Biotherapeutics Insider Trading
Calidi Biotherapeutics insiders have not reported any transactions in the past 90 days.
The most recent sale was by Allan Camaisa who sold 850 shares on December 12, 2025. View all transactions in the table on this page.
Insider buying is generally a stronger signal than insider selling, since insiders may sell for personal reasons (diversification, taxes) but typically buy only when they believe the stock is undervalued. AltIndex uses insider transaction patterns alongside 25+ other signals in the AI Score.
Camaisa Allan has sold the most CLDI stock in the last 2 years, with a total value of $17,000.
The total value of insider transactions for Calidi Biotherapeutics in the last 2 years is negative, amounting to -$17,000. This suggests that insiders have predominantly sold shares, which could reflect various personal or financial considerations rather than a straightforward outlook on the company's future performance.
